Cabaletta Bio, Inc. Files 8-K on Financials
Ticker: CABA · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1759138
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cabaletta Bio dropped an 8-K detailing their financials - check it out.
AI Summary
Cabaletta Bio, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The company, incorporated in Delaware, is in the biological products sector and is headquartered in Philadelphia, PA.
Why It Matters
This filing provides investors with crucial updates on Cabaletta Bio's financial health and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Cabaletta Bio, Inc. (company) — Registrant
- 2024-03-21 (date) — Date of Report
- Philadelphia, PA (location) — Principal Executive Offices
- 001-39103 (other) — SEC File Number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on March 21, 2024.
Where is Cabaletta Bio, Inc. headquartered?
Cabaletta Bio, Inc. is headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.
What is Cabaletta Bio, Inc.'s SIC code?
Cabaletta Bio, Inc.'s Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-21 07:12:59
Key Financial Figures
- $0.00001 — ich Registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se
Filing Documents
- d717290d8k.htm (8-K) — 24KB
- d717290dex991.htm (EX-99.1) — 56KB
- g717290g0321023601448.jpg (GRAPHIC) — 4KB
- 0001193125-24-073294.txt ( ) — 219KB
- caba-20240321.xsd (EX-101.SCH) — 3KB
- caba-20240321_lab.xml (EX-101.LAB) — 18KB
- caba-20240321_pre.xml (EX-101.PRE) — 11KB
- d717290d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on March 21, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: March 21, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer